The company aims to use its unique advanced technology to develop and manufacture lifesaving therapeutic blood products. The facility will have the capacity to process one million litres of human plasma per year.
Currently, Australia imports almost half of the essential plasma and blood products used to develop biopharmaceuticals. This new facility will position Aegros to meet the needs of the domestic market and open potential export opportunities in the future.
Once Aegros has secured all necessary approvals and finance, the two-year construction will support an estimated 230 jobs. Aegros also estimates that its facility will create at least 348 long-term jobs across its first 4 years of operation.